Brimonidine vs. Oxymetazoline: Mirvaso and Rhofade for Rosacea Redness

Mirvaso (brimonidine 0.33% gel) and Rhofade (oxymetazoline 1% cream) are prescription treatments for the persistent facial redness of rosacea in adults. Both work the same basic way: they tighten the small blood vessels in the skin so the redness fades for several hours, then it gradually comes back. Neither one cures rosacea or treats its bumps and pimples. The biggest practical difference is on their labels. Mirvaso’s label describes a rebound effect, where some people’s redness came back worse than before, plus flushing and redness spreading to new areas. Rhofade’s label doesn’t carry that warning; its most common side effects were skin reactions where the cream went on. Which one fits, if either, is a call to make with a dermatologist.

The two side by side

What “persistent redness” means here

Rosacea shows up in different ways, and these two drugs aim at only one of them: the background redness across the cheeks, nose, chin and forehead that sticks around rather than coming and going. The National Rosacea Society describes it as resembling a blush or sunburn, and notes that in darker skin it may look purple or brown instead of red.

That’s different from bumps and pimples, which have their own treatments, and from visible blood vessels, which these creams don’t remove. If visible vessels bother you most, our post on broken capillaries covers what does help, and lasers or light treatments are usually the route there.

How they work, and why the effect wears off

Both are vasoconstrictors. They squeeze the small blood vessels near the surface, so less blood shows through and the skin looks less red. The Mirvaso label says brimonidine may reduce redness “through direct vasoconstriction.” The Rhofade label says simply that oxymetazoline “acts as a vasoconstrictor.” Oxymetazoline is the same drug found in some decongestant nasal sprays; the cream is a different product made for the face.

Because the effect is mechanical rather than a fix for what’s driving the rosacea, it’s temporary. The American Academy of Dermatology (AAD) says both can fade persistent redness for up to 12 hours, that results tend to peak 3 to 6 hours after applying, and that the color then gradually returns. It’s a daily treatment for how the skin looks, not a cure.

What the trials found

Each drug was tested in two 4-week trials against a plain gel or cream without the drug. Success meant a 2-grade drop in redness on both a doctor’s scale and the patient’s own rating, measured at several points across the day on day 29.

It’s tempting to read that table and crown Mirvaso. Don’t. These were separate trials with different people, and both labels warn that one drug’s trial results can’t be compared directly with another’s. What each set shows is that the drug beat its plain base, and that a minority of people hit the strict success bar.

The trials also lasted only 4 weeks, and the people in them were overwhelmingly white, so there’s little trial data on darker skin.

Rebound redness: the Mirvaso warning

This is the part people search for. Mirvaso’s label says some trial patients reported “a rebound phenomenon, where erythema was reported to return worse compared to the severity at baseline,” and that this appeared to resolve after they stopped using the gel. It also notes that the effect may begin to fade within hours of applying it.

After approval, some people reported redness in areas of the face that weren’t red before, and on the neck and chest, along with more frequent, deeper or brand-new flushing. Others saw skin go pale or too white. In the trials, flushing started anywhere from about 30 minutes to several hours after applying.

In the 4-week trials, redness as a side effect showed up in 4% of people on Mirvaso against 1% on the plain gel, and flushing in 3% against none. In the year-long study, where people could also use other rosacea treatments, flushing was reported by 10% and redness by 8%.

Rhofade’s label has no rebound warning. Its most common side effects in the 4-week trials were skin irritation where it was applied (2%), worsening of rosacea bumps (1%), and itching, redness and pain (about 1% each). In its year-long study, worsening bumps and skin irritation each reached 3%. A label that doesn’t list rebound isn’t a promise you’ll never see it, but it’s a real difference between the two documents.

Who should be careful with either one

Both labels urge caution with circulation problems such as Raynaud’s phenomenon, scleroderma, Sjögren’s syndrome and thromboangiitis obliterans, along with heart disease and blood pressure problems. Mirvaso’s list adds depression. Rhofade’s adds narrow-angle glaucoma, since it may raise the risk of a sudden glaucoma attack.

• Blood pressure medicines. Both labels advise caution with beta-blockers, other blood pressure drugs, heart medicines called cardiac glycosides, and MAO inhibitors.
• Irritated or broken skin. Neither goes on irritated skin or open wounds. Mirvaso’s label notes that some reports of slow heart rate, low blood pressure and dizziness, a few needing hospital care, involved use after laser procedures.
• Allergy. Allergic contact dermatitis to Mirvaso was reported in about 1% of people across its studies, and reports after approval include swelling of the lips, tongue and throat, and hives.
• Kids in the house. Two young children of a Mirvaso trial participant needed hospital care after swallowing the gel, and Rhofade’s label notes serious reactions in children who swallowed oxymetazoline nasal products. Store both out of reach.

Pregnancy and breastfeeding

Neither drug has good data in pregnancy. Mirvaso’s patient leaflet says it isn’t known whether the gel will harm an unborn baby or pass into breast milk, and asks you and your doctor to choose the gel or breastfeeding, not both. Rhofade’s label says there’s no data on the cream in pregnant women, mentions one published analysis linking second-trimester use of oxymetazoline nasal decongestant with a kidney anomaly, and says it isn’t known whether the cream passes into breast milk. Raise pregnancy plans or nursing before a prescription is written.

Gentle basics that sit alongside either one

Both labels steer you away from using these drugs on irritated skin, one more reason to keep the rest of your shelf plain, and sun is a common rosacea trigger. Nothing below substitutes for a prescription. A green-tinted sunscreen hides redness with color, not by changing blood flow.

Prices move constantly, so we link to live listings instead of printing a number that is wrong by the time you read it. Links go to Amazon, which is where a referral gets credited.

CeraVe Hydrating Facial Cleanser is about $15, though the price changes often. It has three ceramides and hyaluronic acid, no added fragrance, and it’s non-comedogenic. CeraVe makes it for normal to dry skin.

La Roche-Posay Toleriane Double Repair Face Moisturizer is about $25. It has ceramide-3, niacinamide, glycerin and the brand’s thermal spring water in a lightweight cream, and it’s fragrance free, oil free and non-comedogenic. La Roche-Posay recommends it for all skin types, including sensitive.

EltaMD UV Skin Recovery Green Tinted SPF 50 is the splurge at about $53. Its only active is zinc oxide 12.9%, with ceramides and centella leaf extract, and EltaMD says its green tint neutralizes the look of redness. Green sits opposite red on the color wheel, which is the idea behind our color-correcting makeup guide.

Cetaphil Sheer Mineral Face Liquid SPF 50 is about $13, with zinc oxide 12% as its only sunscreen active in a thin liquid. Cetaphil says it’s formulated for sensitive skin and works under makeup, it’s water resistant for 80 minutes, and there’s no fragrance in the ingredient list. It’s the easiest budget pick here.

Blue Lizard Sensitive Mineral SPF 50 is about $13 for a 5-ounce tube that does face and body. It uses zinc oxide 10% and titanium dioxide 8%, and Blue Lizard says it’s developed specifically for sensitive skin, hypoallergenic and free of parabens, phthalates and fragrance. If you’re weighing filter types, our chemical vs. physical sunscreen explainer lays out the trade-offs.

Apply any sunscreen 15 minutes before sun and reapply at least every 2 hours outdoors.

If I Were You

If your redness is constant and you want it gone for the workday, ask a dermatologist whether either suits you, knowing the effect lasts hours, not days.

If you’ve read about rebound and it worries you, say so. That warning is on Mirvaso’s label, not Rhofade’s, and your history of flushing matters to the choice.

If you have Raynaud’s, heart or blood pressure problems, or glaucoma, mention it first. All of these are on one or both labels’ caution lists.

If your main issue is bumps and pimples, neither drug is labeled for that, and Rhofade’s trials logged worsening bumps in a small share of people. Other treatments target them.

If you’d rather not add a prescription, a green-tinted mineral sunscreen tones down redness cosmetically. Our guide to calming rosacea redness covers triggers and routine.

Bottom line

Mirvaso and Rhofade both shrink blood vessels to fade the persistent redness of rosacea for part of the day. They don’t cure it, and they don’t treat the bumps. Mirvaso’s label carries a rebound and flushing warning that Rhofade’s doesn’t, while Rhofade’s brings a glaucoma caution. Their trial numbers can’t be stacked side by side. A dermatologist can weigh those trade-offs against your skin and your medical history. Around either one, keep the routine plain and the sunscreen daily. More is in our skin archive.